2025-12-28 - Analysis Report
Okay, here's a comprehensive report on Eli Lilly (LLY) based on the provided data:

**1) Return Rate Comparison and Analysis:**

*   **Company Overview:** Eli Lilly and Co. is a global pharmaceutical company discovering and developing innovative medicines.
*   **Cumulative Return (LLY):** 307.99%
*   **Cumulative Return (VOO - S&P 500):** 103.21%
*   **Divergence:** 204.7 (Relative Divergence: 84.5)

**Analysis:** Eli Lilly has significantly outperformed the S&P 500 (VOO) by a substantial margin, showing a cumulative return almost three times that of the index. The current divergence is 204.7.  The relative divergence of 84.5 suggests that the current outperformance is near the higher end of its historical range compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha  | Beta  | Cap(B)  |
|------------|---------|--------|--------|-------|---------|
| 2015-2017  | 11.0%   | 76.1%  | -17.0% | -0.0  | 75.7    |
| 2016-2018  | 39.0%   | 68.9%  | 24.0%  | -0.0  | 103.7   |
| 2017-2019  | 41.0%   | 68.9%  | 19.0%  | 0.4   | 117.8   |
| 2018-2020  | 34.0%   | 79.8%  | 10.0%  | 0.4   | 151.4   |
| 2019-2021  | 53.0%   | 79.8%  | 7.0%   | 0.5   | 247.6   |
| 2020-2022  | 64.0%   | 79.8%  | 65.0%  | 0.4   | 328.0   |
| 2021-2023  | 125.0%  | 78.9%  | 124.0% | 0.2   | 522.6   |
| 2022-2024  | 134.0%  | 81.2%  | 113.0% | 0.2   | 692.1   |
| 2023-2025  | 199.0%  | 83.5%  | 132.0% | 0.2   | 966.2   |

**Analysis:**

*   **CAGR:** The Compound Annual Growth Rate has been steadily increasing over the periods analyzed, with a significant jump in recent years.
*   **MDD:** The Maximum Drawdown remains high, indicating substantial risk, although relatively stable.
*   **Alpha:** The Alpha is generally positive and has increased dramatically in recent periods, indicating that the stock is generating excess returns above what would be expected based on its beta.
*   **Beta:** The Beta is consistently low.
*   **Cap(B):** The market capitalization has increased substantially over the periods analyzed, reflecting the company's growth.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 1077.75
*   **Last Market Change:** Price: 1077.75, Previous Close: 1076.98, Change: 0.07
*   **5-day SMA:** 1074.86
*   **20-day SMA:** 1040.49
*   **60-day SMA:** 952.21

**Analysis:** The stock price is above all three moving averages (5-day, 20-day, and 60-day), indicating an uptrend. The 5-day SMA is close to the current price, while the 20-day and 60-day SMAs are further below, supporting the view that the stock has been trending upwards recently. The small change between the current and previous close suggests recent price stability.

**3) RSI, PPO, and Other Indicators:**

*   **MRI:** 1.0 (High Investment Recommended)
*   **RSI:** 69.37
*   **PPO:** -0.03
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-11-03)
*   **Recent Relative Divergence Change (20 days):** 5.8 (+) (Short-term increase)
*   **Expected Return (%):** 49.2

**Analysis:**

*   **MRI of 1.0** suggests a strong buy signal based on this market risk indicator.
*   **RSI of 69.37** is approaching the overbought threshold (70), suggesting the stock may be due for a minor pullback.
*   **PPO of -0.03** indicates that the short-term moving average is slightly below the long-term moving average, which could suggest a potential change in momentum, although the value is very close to zero.
*   **Hybrid Signal**: Recommends buying the stock, given its very high MRI value.
*   **Short-term divergence increase**: Reinforces the recent upward trend.
*   **Expected Return of 49.2%** is exceptionally high, suggesting strong confidence in the stock's long-term growth potential.

**4) Recent News & Significant Events:**

*   **Positive Sentiment:** Articles discuss Eli Lilly as a top stock split candidate and highlight its potential for 2026.
*   **Mixed Sentiment:** One article mentions a rating downgrade, suggesting some analysts are becoming more cautious.
*   **Price Reductions:** News of price cuts for Zepbound caused a temporary stock drop, offering a potential buying opportunity according to one article.
*   **GLP-1 Pricing, Pill Competition, and Retatrutide Data**: Suggesting that GLP‑1 Pricing, Pill Competition, and Retatrutide Data are major factors that will shape the 2026 outlook.
*   **Institutional Investment:**  Cwm LLC holds a significant position in LLY, indicating confidence from institutional investors.

**Analysis:** Recent news paints a mixed picture. Positive sentiment is driven by potential stock splits and positive outlooks, while some caution is warranted due to price cuts and potential downgrades. Overall, the news seems slightly positive, as long-term growth prospects are highlighted.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.70)
*   **Target Price:** Average: 1093.22, High: 1500.00, Low: 770.00

**Analysis:** Analyst consensus is strongly bullish with a "Buy" rating. The average target price suggests a potential upside from the current price, but the wide range (770-1500) reflects some uncertainty among analysts. The lack of recent rating changes suggests that analysts' opinions have remained relatively stable.

**5) Recent Earnings Analysis:**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-10-30 | 6.22  | 17.60 B$    |
| 2025-08-07 | 6.3   | 15.56 B$    |
| 2025-05-01 | 3.07  | 12.73 B$    |
| 2024-10-30 | 1.08  | 11.44 B$    |
| 2025-10-30 | 1.08  | 11.44 B$    |

**Analysis:**

*   **EPS:** Earnings per share has increased significantly, with a recent dip.
*   **Revenue:** Revenue has shown strong growth over the past few quarters, indicating increasing sales and demand for the company's products.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue     | Profit Margin |
|--------------|-------------|---------------|
| 2025-09-30   | $17.60B     | 82.91%        |
| 2025-06-30   | $15.56B     | 84.27%        |
| 2025-03-31   | $12.73B     | 82.53%        |
| 2024-12-31   | $13.53B     | 82.24%        |
| 2024-09-30   | $11.44B     | 81.02%        |

**Capital and Profitability:**

| Quarter      | Equity      | ROE       |
|--------------|-------------|-----------|
| 2025-09-30   | $23.79B     | 23.46%    |
| 2025-06-30   | $18.27B     | 30.98%    |
| 2025-03-31   | $15.76B     | 17.50%    |
| 2024-12-31   | $14.19B     | 31.07%    |
| 2024-09-30   | $14.24B     | 6.81%     |

**Analysis:**

*   **Revenue Growth:** Consistent revenue growth indicates strong market demand.
*   **High Profit Margins:** Consistently high profit margins (above 80%) show excellent cost management and pricing power.
*   **Equity Growth:** Equity has been increasing, suggesting the company is retaining earnings and growing its asset base.
*   **ROE Variation:** The Return on Equity has been volatile.

**7) Comprehensive Analysis (Summary):**

Eli Lilly is a high-growth stock that has significantly outperformed the S&P 500. The company has demonstrated strong revenue and earnings growth, accompanied by high profit margins. Analyst sentiment is bullish, with a consensus "Buy" rating and a substantial average target price, suggesting additional upside potential. The MRI also recommends a high investment in the stock.

However, several factors warrant caution:

*   **High Valuation:** The stock is potentially overbought based on its RSI. The high Maximum Drawdown also suggests substantial risk.
*   **Market Risk:** Potential rating downgrades, price cuts, and fluctuations in analyst target prices demonstrate some degree of uncertainty.

**Overall Recommendation:**

Based on the provided data, Eli Lilly appears to be a strong investment with significant growth potential. However, investors should be aware of the inherent risks associated with high-growth stocks and consider a diversified portfolio to mitigate risk. Monitoring news flow, earnings reports, and analyst ratings will be crucial for making informed investment decisions. Given the slightly overbought RSI, a potential strategy could be to gradually accumulate shares on pullbacks.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.